ALLO

Allogene Therapeutics Inc

1.18

Oct 23 • 10:44 AM ET -0.07 (-5.94%)

Healthcare Biotechnology USA Small NASD

Peers: CRBU CLLS FATE SANA NKTX IPSC ACET AUTL LEGN GILD

| Held by: VTI XBI IWM VXF IWN FESM VTWO IBB DFAS SCHA

Index	RUT
Market Cap	406.22M
Enterprise Value	152.63M
Income	-165.49M
Sales	4.64M
Book/sh	1.26
Cash/sh	0.96
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	152
IPO	Oct 11, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	87.55
P/B	0.93
P/C	1.22
P/FCF	-
EV/EBITDA	-
EV/Sales	32.90
Quick Ratio	10.72
Current Ratio	10.72
Debt/Eq	0.18
LT Debt/Eq	0.16
Option/Short	Yes / Yes

EPS (ttm)	-0.67
EPS next Y	-0.64
EPS next Q	-0.15
EPS this Y	30.88%
EPS next Y	-5.70%
EPS next 5Y	13.94%
EPS past 3/5Y	28.61% 16.08%
Sales past 3/5Y	- -
EPS Y/Y TTM	40.16%
Sales Y/Y TTM	-100.00%
EPS Q/Q	44.26%
Sales Q/Q	-
Earnings	Aug 12 AMC
EPS/Sales Surpr.	24.15% 186372.00%

Insider Own	25.37%
Insider Trans	-0.04%
Inst Own	71.29%
Inst Trans	40.45%
ROA	-32.43%
ROE	-42.39%
ROIC	-32.67%
Gross Margin	-151.47%
Oper. Margin	-3886.14%
Profit Margin	-3566.68%
SMA20	-16.51%
SMA50	-30.95%
SMA200	-40.90%
Trades

Shs Outstand	345.35M
Shs Float	257.83M
Short Float	21.57%
Short Ratio	9.68
Short Interest	55.61M
52W High	4.46 -73.64%
52W Low	1.04 13.06%
Volatility	5.46% 5.49%
ATR (14)	0.08
RSI (14)	22.58
Beta	0.74
Rel Volume	3.37
Avg Volume	5.75M
Volume	4,457,163

Perf Week	-10.24%
Perf Month	-29.59%
Perf Quarter	-32.81%
Perf Half Y	-49.10%
Perf YTD	-14.18%
Perf Year	-2.83%
Perf 3Y	-57.71%
Perf 5Y	-92.57%
Perf 10Y	-
Recom	1.27
Target Price	8.75
Prev Close	1.25
Price	1.18
Change %	-5.94%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-26	Upgrade	JP Morgan	Underweight → Neutral
Apr-10-26	Resumed	Jefferies	Buy	$6
Jan-09-26	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$5
Oct-10-25	Downgrade	JP Morgan	Neutral → Underweight
May-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Mar-14-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$5
Aug-08-24	Resumed	Oppenheimer	Outperform	$13 → $11
May-31-24	Initiated	Piper Sandler	Overweight	$11
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Dec-08-23	Initiated	Citigroup	Buy	$7
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform	$28
Mar-21-23	Initiated	Bernstein	Mkt Perform	$6
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight	$20 → $11
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform	$12
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform	$24 → $9
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy	$9 → $32
Jun-03-22	Initiated	Robert W. Baird	Neutral	$11

Show Previous Ratings

Sep-15-26 07:11AM	CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot (Stocktwits)
Sep-02-26 08:32AM	Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts (BioPharma Dive)
08:30AM	Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker (GlobeNewswire)
Aug-31-26 08:30AM	Allogene Therapeutics Announces Participation in September Investor Conference (GlobeNewswire)
Aug-13-26 01:01AM	Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlights: RMAT Designation and Rapid ... (GuruFocus.com)
04:12PM	Loading…
Aug-12-26 04:12PM	Allogene Therapeutics: Q2 Earnings Snapshot (Associated Press)
04:05PM	Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update (GlobeNewswire)
Aug-11-26 09:20AM	Allogene Therapeutics Inc (ALLO) Q2 2026 Earnings Report Preview: What To Look For (GuruFocus.com)
Aug-04-26 08:30AM	Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update (GlobeNewswire)
Jul-29-26 08:30AM	Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma (GlobeNewswire) +9.04%
Jul-15-26 08:30AM	Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors (GlobeNewswire)
Jun-30-26 04:10PM	Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial (Exec Edge) -6.31%
Jun-09-26 05:19PM	FDA Clears Imvivas Dual-Target CAR-T for Autoimmune Diseases (Exec Edge)
May-28-26 05:02PM	Allogene Therapeutics Announces Planned CEO Succession (GlobeNewswire)
May-26-26 08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire) +6.00%
01:00AM	Loading…
May-14-26 01:00AM	Allogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Highlights: Promising Trial Results and ... (GuruFocus.com) -8.15%
May-13-26 04:08PM	Allogene Therapeutics: Q1 Earnings Snapshot (Associated Press)
04:02PM	Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update (GlobeNewswire)
May-06-26 08:30AM	Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update (GlobeNewswire) +6.45%
Apr-21-26 08:30AM	Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia (GlobeNewswire)
Apr-20-26 08:30AM	Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 (GlobeNewswire)
Apr-16-26 04:01PM	Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock (GlobeNewswire) +9.22%
Apr-15-26 10:30AM	BC-Most Active Stocks (Associated Press)
08:30AM	Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases (GlobeNewswire)
Apr-14-26 09:50PM	Allogene Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -25.49%
Apr-13-26 04:01PM	Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock (GlobeNewswire) +12.50%
10:30AM	BC-Most Active Stocks (Associated Press)
08:00AM	Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma (Business Wire)
07:30AM	Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL (GlobeNewswire)
Apr-10-26 04:02PM	Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 (GlobeNewswire) -6.53%
11:03PM	Loading…
Mar-12-26 11:03PM	Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlights: Financial Stability and ... (GuruFocus.com) -6.08%
04:13PM	Allogene Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:02PM	Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update (GlobeNewswire)
Mar-09-26 09:00AM	Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus (Zacks) +8.70%
Mar-03-26 10:34PM	Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen (MarketBeat)
Mar-02-26 08:30AM	Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update (GlobeNewswire)
Feb-26-26 11:44AM	Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up (Zacks) +7.91%
10:54AM	ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance (Zacks)
Feb-18-26 07:00PM	Allogene Therapeutics Teases April ALPHA3 Data as cema-cel Targets MRD+ LBCL in Remission (MarketBeat) +5.09% -6.17%
Feb-11-26 09:40AM	Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? (Zacks)
Feb-05-26 08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire) -9.44%
07:58AM	Rapid Innovation is Reshaping Oncology: Stocks in Focus (Zacks)
Jan-26-26 09:40AM	Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? (Zacks) -12.21%
Jan-09-26 09:40AM	Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? (Zacks) +14.77%
Jan-08-26 08:30AM	Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T (GlobeNewswire)
Dec-15-25 05:39PM	Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis (GlobeNewswire)
Nov-10-25 08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-25 11:20AM	Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales (Zacks) +12.38%
12:11AM	Allogene Therapeutics Inc (ALLO) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-06-25 04:26PM	Allogene Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -5.41%
04:05PM	Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Nov-03-25 09:04AM	Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting (GlobeNewswire)
Oct-30-25 08:30AM	Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update (GlobeNewswire)
Oct-14-25 11:24AM	TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals (Zacks)
Oct-13-25 01:06PM	Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain (Zacks)
10:15AM	TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder (Zacks)
Oct-10-25 12:21PM	CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza (Zacks) -18.54%
10:27AM	OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data (Zacks)
Oct-08-25 11:18AM	KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure (Zacks) +8.89%
11:15AM	AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study (Zacks)
Oct-07-25 11:56AM	MRK Expands Tulisokibart Program in Three New Inflammatory Diseases (Zacks)
Sep-16-25 12:54PM	Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update (Zacks)
Sep-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report? (Zacks)
Sep-08-25 09:42AM	Investing in Oncology: 3 Cancer Stocks With Promising Pipelines (Zacks)
Sep-05-25 11:00AM	AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA (Zacks)
10:04AM	AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia (Zacks)
Aug-27-25 08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conference (GlobeNewswire)
Aug-14-25 11:11AM	Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
03:15AM	Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
Aug-13-25 04:12PM	Allogene Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Aug-12-25 09:34AM	Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-06-25 08:30AM	Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update (GlobeNewswire) -5.36%
Aug-01-25 08:30AM	Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma (GlobeNewswire) -12.20%
07:10AM	Regeneron cancer bispecific rejected again; Allogene discloses trial death (BioPharma Dive)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire) +16.90%
Jul-21-25 09:41AM	Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025 (Zacks) +5.60%
Jun-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report? (Zacks)
Jun-04-25 12:00PM	All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy (Zacks)
Jun-01-25 10:45AM	Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO (GlobeNewswire)
May-23-25 08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-22-25 05:17PM	Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel (GlobeNewswire)
May-20-25 09:11AM	REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research (Zacks) +6.42%
May-16-25 06:36AM	Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff (BioPharma Dive)
May-15-25 11:04AM	Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) +14.40%
09:43AM	Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays (GuruFocus.com)
09:35AM	Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-14-25 11:41AM	Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus (Zacks) -15.68%
10:46AM	Q1 2025 Allogene Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
09:00AM	EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line (Zacks)
06:29AM	Allogene's Q1 Earnings In Line With Estimates, Sales Nil (Zacks)
03:18AM	Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-13-25 04:11PM	Allogene Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
12:07PM	Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
08:42AM	Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
May-12-25 09:40AM	Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
09:20AM	RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parker Geoffrey M.	Officer	Oct 21 '26	Proposed Sale	1.34	36,342	48,698		Oct 21 07:48 PM
Douglas Earl Martin	SVP, General Counsel	Aug 21 '26	Sale	2.12	29,697	62,958	488,267	Aug 25 04:43 PM
Douglas Earl Martin	Officer	Aug 21 '26	Proposed Sale	2.12	29,697	62,958		Aug 21 07:26 PM
Kazam Joshua A	Director	Jun 18 '26	Option Exercise	0.00	47,700	0	398,463	Jun 23 04:35 PM
Yoshiyama Annie	SVP, Finance	Apr 21 '26	Sale	2.31	9,586	22,144	124,517	Apr 23 04:16 PM
Yoshiyama Annie	Officer	Apr 21 '26	Proposed Sale	2.31	9,586	22,103		Apr 21 08:22 PM
Beneski Benjamin Machinas	SVP, Chief Technical Officer	Mar 31 '26	Sale	2.50	2,867	7,168	195,338	Apr 02 04:47 PM
Beneski Benjamin Machinas	Officer	Apr 01 '26	Proposed Sale	2.50	2,867	7,168		Apr 01 07:13 PM
Beneski Benjamin Machinas	SVP, Chief Technical Officer	Mar 16 '26	Sale	2.47	4,835	11,942	198,205	Mar 18 04:06 PM
Chang David D	President and CEO	Mar 16 '26	Sale	2.47	47,763	117,975	5,150,599	Mar 18 04:05 PM
Beneski Benjamin Machinas	Officer	Mar 16 '26	Proposed Sale	2.47	4,835	11,928		Mar 16 08:20 PM
Chang David D	Officer	Mar 16 '26	Proposed Sale	2.47	47,763	117,827		Mar 16 08:05 PM
Beneski Benjamin Machinas	SVP, Chief Technical Officer	Mar 02 '26	Sale	2.60	7,132	18,543	203,040	Mar 04 05:42 PM
Beneski Benjamin Machinas	Officer	Mar 02 '26	Proposed Sale	2.60	7,132	18,541		Mar 02 09:04 PM
Beneski Benjamin Machinas	SVP, Chief Technical Officer	Feb 02 '26	Sale	1.73	7,549	13,060	210,172	Feb 04 05:20 PM
Chang David D	President and CEO	Feb 02 '26	Sale	1.80	95,269	171,484	5,185,862	Feb 04 05:18 PM
Parker Geoffrey M.	CHIEF FINANCIAL OFFICER	Feb 02 '26	Sale	1.76	24,001	42,242	1,252,795	Feb 04 05:16 PM
Douglas Earl Martin	SVP, General Counsel	Feb 02 '26	Sale	1.76	22,900	40,304	564,948	Feb 04 05:12 PM
Yoshiyama Annie	SVP, Finance	Feb 02 '26	Sale	1.72	4,167	7,167	130,322	Feb 04 05:09 PM
Roberts Zachary	EVP of R&D	Feb 02 '26	Sale	1.77	35,700	63,189	581,166	Feb 04 05:07 PM
EARL DOUGLAS	Officer	Feb 02 '26	Proposed Sale	1.76	22,900	40,215		Feb 02 05:17 PM
GEOFFREY M PARKER	Officer	Feb 02 '26	Proposed Sale	1.76	24,001	42,189		Feb 02 05:16 PM
ZACHARY J ROBERTS	Officer	Feb 02 '26	Proposed Sale	1.77	35,700	63,353		Feb 02 05:16 PM
ANNIE T YOSHIYAMA	Officer	Feb 02 '26	Proposed Sale	1.72	4,167	7,178		Feb 02 05:15 PM
DAVID CHANG	Officer	Feb 02 '26	Proposed Sale	1.80	243,976	438,522		Feb 02 04:51 PM
BENJAMIN M BENESKI	Officer	Feb 02 '26	Proposed Sale	1.73	16,823	29,052		Feb 02 04:49 PM
Roberts Zachary	EVP of R&D	Jan 21 '26	Sale	1.56	26,269	40,980	616,866	Jan 23 04:15 PM
Roberts Zachary	Officer	Jan 21 '26	Proposed Sale	1.56	26,269	40,929		Jan 21 07:53 PM
Kazam Joshua A	Director	Dec 18 '25	Option Exercise	0.00	47,700	0	350,763	Dec 22 06:57 PM
Beneski Benjamin Machinas	SVP, Chief Technical Officer	Nov 17 '25	Sale	1.22	786	959	217,721	Nov 19 04:09 PM
Beneski Benjamin Machinas	Officer	Nov 17 '25	Proposed Sale	1.22	786	959		Nov 17 07:14 PM

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

M.D.Dr. Arie S. Belldegrun F.A.C.S.

Ph.D.Dr. Zachary J. Roberts M.D.

Co-Founder & DirectorMr. Joshua A. Kazam

Ph.D.Dr. David D. Chang M.D.

Executive VP & CFOMr. Geoffrey M. Parker

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALLO

Allogene Therapeutics Inc

Upgrade your Finviz experience